Sandoz Group AG (SWX:SDZ)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 16.49B |
| Revenue (ttm) | 9.41B |
| Net Income (ttm) | n/a |
| Shares Out | 430.70M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | 13.78 |
| Dividend | 0.60 (1.57%) |
| Ex-Dividend Date | Apr 17, 2025 |
| Volume | 972,228 |
| Average Volume | 1,394,782 |
| Open | 38.42 |
| Previous Close | 38.28 |
| Day's Range | 38.15 - 38.68 |
| 52-Week Range | 25.33 - 45.10 |
| Beta | n/a |
| RSI | 45.60 |
| Earnings Date | Mar 5, 2025 |
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland. [Read more]
Full Company ProfileNews
Thanks to $60 Million Federal Investment - DELPHARM TO MODERNIZE ITS FACILITIES AND ENSURE CONTINUED PRODUCTION OF STERILE INJECTABLE MEDICINES IN BOUCHERVILLE
BOUCHERVILLE, QC , March 18, 2025 /CNW/ - Delpharm, a world leader in pharmaceutical outsourcing, announced that it has reached an agreement with the Government of Canada to modernize its injectable m...
Sandoz Group AG (SDZNY) (Q4 2024) Earnings Call Highlights: Record Sales and Strategic Growth ...
Sandoz Group AG (SDZNY) (Q4 2024) Earnings Call Highlights: Record Sales and Strategic Growth Initiatives
US Tariffs Will Raise Drug Prices for Patients, Sandoz CEO Says
The US shift toward steep tariffs will likely make drugs more expensive and limit access for patients, according to one of the world’s largest makers of generic medicines.
Health Care Roundup: Market Talk
Find insight on Bayer, Sandoz, Fresenius and more in the latest Market Talks covering Health Care.
Sandoz Group AG Non-GAAP EPS of $2.71, revenue of $10.36B; initiates FY25 outlook
NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects
A cost-saving effort by NHS England to transition multiple sclerosis (MS) patients from Biogen Inc’s (NASDAQ: BIIB) Tysabri (natalizumab) to the biosimilar drug Tyruko has led to significant side eff...
Sandoz launches biosimilar Pyzchiva in U.S. for all approved Stelara indications
MS patients suffer side-effects after NHS England switches to cheaper drug
Scores of people experience complications after change from Tysabri to Tyruko as part of NHS drive to save money ‘It was awful for me’: one MS patient shares her experience with Tyruko Scores of peopl...
Intra-Cellular Therapies Stock Soars 19% After Securing Major Patent Victory Over Sandoz
Intra-Cellular Therapies Stock Soars 19% After Securing Major Patent Victory Over Sandoz
Intra-Cellular settles Caplyta patent dispute with Sandoz
Intra-Cellular Therapies (ITCI) stock jumps as the company settles a patent dispute with Sandoz (SDZNY) over Caplyta. Read more here.
Intra-Cellular Therapies Inc (ITCI) Announces Settlement with Sandoz Over CAPLYTA Patent Litigation
Intra-Cellular Therapies Inc (ITCI) Announces Settlement with Sandoz Over CAPLYTA Patent Litigation
Caplin Point gets USFDA approval for eye drops – Difluprednate Ophthalmic Emulsion
Caplin Point Laboratories announced receiving final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Difluprednate Ophthalmic Emulsion 0.05...
Sandoz Charts Path to Swift Generic Ozempic Launch in Canada
Sandoz Group AG plans to use the Canadian market as a trial balloon for generic Ozempic, challenging Novo Nordisk A/S with a copycat version as soon as 2026.
Sandoz Charts Path to Swift Generic Ozempic Launch in Canada
Sandoz Group AG plans to use the Canadian market as a trial balloon for generic Ozempic, challenging Novo Nordisk A/S with a copycat version as soon as 2026.
Glenmark Pharmaceuticals shares in focus as company launches Travoprost Ophthalmic Solution in U.S.
Glenmark Pharmaceuticals Inc., USA, headquartered in Mahwah, New Jersey, has announced the launch of Travoprost Ophthalmic Solution USP, 0.004% (Ionic Buffered Solution), marking a significant additio...
Glenmark Pharmaceuticals USA launches Travoprost Ophthalmic Solution USP
Glenmark Pharmaceuticals Inc., USA, headquartered in Mahwah, New Jersey, has announced the launch of Travoprost Ophthalmic Solution USP, 0.004% (Ionic Buffered Solution). This product is a bioequivale...
Sandoz Group: Moving To A 'Hold' After A 50% Move
Sandoz Group's stock has surged nearly 50% since my last article, driven by strong performance in the generics and biosimilars sector. Read more here.
Axsome Therapeutics reaches agreement to dismiss patent litigation with Sandoz
Sandoz Group AG (SDZNY) (Q2 2024) Earnings Call Transcript Highlights: Strong Biosimilars ...
Sandoz Group AG (SDZNY) (Q2 2024) Earnings Call Transcript Highlights: Strong Biosimilars Growth and Raised Sales Guidance
Half Year 2024 Sandoz Group AG Earnings Call Transcript
Half Year 2024 Sandoz Group AG Earnings Call Transcript
Sandoz Group Non-GAAP EPS of $1.12, revenue of $5B
Sandoz Group AG (SDZNY) Q2 2024 Earnings Call Transcript
Sandoz Group AG 2024 Q2 - Results - Earnings Call Presentation
Won't see major development in weight loss indication drugs in EU or U.S. until 2030, Sandoz CEO says
Richard Saynor, CEO of Sandoz, discusses the firm's half-year results and shares his outlook for innovation in the weight loss drug market.
Generic weight-loss drugs? They’re coming — eventually, executive says
Sandoz, the generics drugmaker spun off from Novartis, is going to get into making cheap versions of the wildly popular GLP-1 class of drugs to treat diabetes and weight loss. But it may take a while.